Histone Acetyltransferase
HATs; HAT
Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular proteins such as histones, transcription factors, nuclear receptors, and enzymes. HATs are crucial for chromatin restructuring and transcriptional regulation in eukaryotic cells. HATs have been shown to play a role in diseases ranging from cancer and inflammatory diseases to neurological disorders, both through acetylations of histone proteins and non-histone proteins.
HATs can be grouped into at least five different subfamilies (HAT1, Gcn5/PCAF, MYST, p300/CBP, and Rtt109). HATs mediate many different biological processes including cell-cycle progression, dosage compensation, repair of DNA damage, and hormone signaling. Aberrant HAT function is correlated with several human diseases including solid tumors, leukemias, inflammatory lung disease, viral infection, diabetes, fungal infection, and drug addiction.
Histone Acetyltransferase Isoform Specific Products
All Product Categories
-
Histone Acetyltransferase Inhibitors
(184)
View all products
-
Histone Acetyltransferase Agonist
(1)
View all products
-
Histone Acetyltransferase Activators
(13)
View all products
-
Histone Acetyltransferase Modulators
(3)
View all products
-
Histone Acetyltransferase Degraders
(39)
View all products
-
Histone Acetyltransferase Controls
(5)
View all products
-
Histone Acetyltransferase Substrates
(5)
View all products
-
Histone Acetyltransferase Ligands
(11)
View all products
-
Histone Acetyltransferase Related Products (288)
Related Products (288)
-
Antibodies (25)
-
Histone Acetyltransferase Isoform Comparison
-
KAT6A-IN-2
0 ImagesCat. No.: HY-162995CAS No.: 2991087-74-0KAT6A-IN-2 (compund 7) is a KAT6A inhibitor.
-
SYY-B085-1
0 ImagesCat. No.: HY-138945CAS No.: 2379416-47-2SYY-B085-1 is a histone acetyltransferase (HAT) inhibitor extracted from patent WO2019201291A1.
-
XYD129
0 ImagesCat. No.: HY-161710XYD129 is a CBP/p300 PROTAC degrader. XYD129 potently binds to CBP, p300 and CRBN proteins, with IC50 values of 0.021 μM, 0.03 μM and 0.18 μM, respectively. XYD129 forms a ternary CRBN-CBP/p300 complex and induces CBP/p300 degradation via the ubiquitin-proteasome system. XYD129 inhibits tumor growth and suppresses the proliferation of acute myeloid leukemia cells. XYD129 can be used in studies related to acute myeloid leukemia.
-
cPP12-2-Lys
0 ImagesCat. No.: HY-P11856cPP12-2-Lys is a cyclic cell-penetrating peptide that serves as a negative control, i.e., it lacks any NatD bisubstrate moiety. cPP12-2-Lys is not a NatD inhibitor (IC50 = 9500 nM), but it possesses excellent cell-penetrating ability and can mediate the entry of conjugated bisubstrate inhibitors into non-small cell lung cancer (NSCLC) cells. cPP12-2-Lys can be used in NSCLC research.
-
CBP/p300 ligand 4
0 ImagesCat. No.: HY-161495CAS No.: 3040120-71-3CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC50 of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300.
-
Y08284
0 ImagesCat. No.: HY-142772CAS No.: 2688745-47-1Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity.
-
KAT2A degrader-2
0 ImagesCat. No.: HY-187169KAT2A degrader-2 is a selective molecular glue degrader targeting KAT2A, with a DC50 of 22 nM in Kelly cells. KAT2A degrader-2 acts as a molecular glue to recruit KAT2A to CRBN, forming a ternary complex that drives the polyubiquitination and proteasome-dependent degradation of KAT2A. KAT2A degrader-2 reduces the acetylation level of histone H3 lysine 9 via the ubiquitin-like and proteasome-dependent pathway. KAT2A degrader-2 can be used for the research of acute myeloid leukemia.
-
Y08175
0 ImagesCat. No.: HY-142743CAS No.: 2223014-57-9Y08175 is a potent CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC50s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer.
-
ZX079
0 ImagesCat. No.: HY-181854CAS No.: 3124583-65-6ZX079 is a dual BRD4 and CBP PROTAC degrader with a BRD4 DC50 value of 0.035 nM and a CBP DC50 value of < 0.02 nM. ZX079 induces dose- and time-dependent degradation of BRD4 and CBP proteins through recruitment of the cereblon E3 ligase. ZX079 induces apoptosis in MV4-11 and MOLM-13 cells, reduces tumor growth in an acute myeloid leukemia xenograft model. ZX079 can be used for the research of acute myeloid leukemia.
-
MNN-02-155
0 ImagesCat. No.: HY-173641CAS No.: 3067681-22-2MNN-02-155 is a bivalent molecular glue with with dual binding to p300/CBP and BCL6. MNN-02-155 induces potent activation of the BCL6-target reporter gene and cell death. MNN-02-155 can be used for the study of diffuse large B cell lymphomas (DLBCLs).
-
CBP/p300 ligand 10
0 ImagesCat. No.: HY-181852CAS No.: 3098454-51-1CBP/p300 ligand 10 (Compound 3-E) is a CBP/p300 degrader. CBP/p300 ligand 10 also serves as a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) and can be used to synthesize the PROTAC CBP/p300 Degrader-2 (HY-181261).
-
CZL-077
0 ImagesCat. No.: HY-180804CAS No.: 3032444-06-4CZL-077 is a potent, selective, and orally active p300/CBP bromodomain (BRD) inhibitor (p300 IC50 = 0.034 μM, CBP IC50 = 0.052 μM) exhibiting high selectivity over the BRDs of BET proteins (BRD2/3/4). CZL-077 inhibits cell growth with IC50 values of 0.024 μM and 5.6 μM in OPM-2 and 22RV1 cells, respectively. CZL-077 shows antitumor efficacy in OPM-2 and 22RV1 xenograft mouse models. CZL-077 can be used for multiple myeloma and prostate cancer research.
-
CZL-046
0 ImagesCat. No.: HY-168148SCAS No.: 3032444-02-0CZL-046 (compund 29) is an oral p300 bromodomain inhibitor.
-
WIZ degrader 3
0 ImagesCat. No.: HY-163819CAS No.: 2839637-72-6WIZ degrader 3 (Compound 29) is a molecular glue degrader for widely interspaced zinc finger motifs (WIZ), with an AC50 of 6.4 nM. WIZ degrader 3 induces the expression of fetal hemoglobin (HbF), with an EC50 of 45 nM. WIZ degrader 3 can be used for the research of blood disorders, such as sickle cell disease and β- thalassemia.
-
PRMT/HKMT-IN-1
0 ImagesCat. No.: HY-114510CAS No.: 1020399-52-3PRMT/HKMT-IN-1 is an epigenetic multi-target protein arginine methyltransferases (PRMTs) and histone lysine methyltransferases (HKMTs) inhibitor. PRMT/HKMT-IN-1 inhibits Aspergillus nidulans RmtA with an IC50 of 29 μM. PRMT/HKMT-IN-1 inhibits human PRMT1, p300/CBP HAT, CARM1, SET7, SIRT1 and SIRT2. PRMT/HKMT-IN-1 inhibits methylation of histone H3K4, H4R3, and H3R17 residues. CBP/p300-IN-23 induces apoptosis, arrests cell cycle in S phase, and triggers granulocytic differentiation in leukemia cells. PRMT/HKMT-IN-1 can be used for the research of leukemia.
-
Anacardic Acid (Standard)
0 ImagesSynonyms: Hydroginkgolic acid (Standard); Ginkgolic Acid C15:0 (Standard)Anacardic Acid (Standard) is the analytical standard of Anacardic Acid. This product is intended for research and analytical applications. Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC50s of ～8.5 μM and ～5 μM, respectively.
-
KAT6-IN-4
0 ImagesCat. No.: HY-177445CAS No.: 2901797-38-2KAT6-IN-4 (Compound Example 2) is a selective lysine acetyltransferase 6 (KAT6) inhibitor. KAT6-IN-4 suppresses transcription of oncogenes like ERα. KAT6-IN-4 demonstrates potent antitumor efficacy in ER+/HER2- breast cancer xenografts. KAT6-IN-4 is promising for research of KAT6-driven malignancies (e.g., breast cancer, NSCLC).
